Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing -- Ignore unavailable to you. Want to Upgrade?

To: Henrik who wrote (27057)	9/20/2001 11:29:35 AM
From: Dale Baker	Respond to of 118717

Yes, the chat server must still be down - haven't heard from the support folks yet.

To: Henrik who wrote (27057)	9/20/2001 11:40:19 AM
From: Dale Baker	Respond to of 118717

I just added some ALGX March 12.5 calls. Market is pricing companies like the economy has come to a halt forever. Total mirror image of the market top in early 2000.

To: Henrik who wrote (27057)	9/27/2001 6:50:56 AM
From: Bocor	Read Replies (2) \| Respond to of 118717

FDA OKs Visible Genetics' HIV Genotyping System 26 Sep 19:07 NEW YORK -(Dow Jones)- Visible Genetics Inc. (VGIN) received approval from the U.S. Food and Drug Administration to market its Trugene HIV-1 Genotyping Kit and OpenGene DNA sequencing system. In a press release Wednesday, the company said this is the first HIV drug resistance test to receive clearance from the FDA. Toronto-based Visible Genetics submitted its Trugene HIV-1 Genotyping Kit and OpenGene system to the FDA on Sept. 5, 2000 as an "integrated system" comprised of the chemistry, hardware, software and interpretive patient report necessary to generate test results. The report provides information to the physician about which antiretroviral drugs are likely to be effective in treating the HIV infection of an individual patient, the company said.